Gemcitabine has been shown recently to have clinical activity as a cytotoxic agent in patients with advanced pancreatic cancer and is known to be a potent radiation sensitizer of human pancreatic cancer cells in vitro. This phase-I trial is designed to determine the maximum tolerable dose (MTD) of gemcitabine when combined with radiation therapy in the treatment of patients with locally advanced, unresectable pancreatic cancer.
Showing the most recent 10 out of 1380 publications